TY  - JOUR
AU  - Longo-Muñoz, F
AU  - Argiles, G
AU  - Tabernero, J
AU  - Cervantes, A
AU  - Gravalos, C
AU  - Pericay, C
AU  - Gil-Calle, S
AU  - Mizuguchi, H
AU  - Carrato-Mena, A
AU  - Limon, M L
AU  - Garcia-Carbonero, R
PY  - 2016
DO  - 10.1007/s12094-016-1528-7
UR  - http://hdl.handle.net/10668/10295
T2  - Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
AB  - TAS-102 is a combination of the thymidine-based nucleoside analog trifluridine and the thymidine phosphorylase inhibitor tipiracil. Efficacy and safety of TAS-102 in patients with metastatic colorectal cancer (mCRC) refractory or intolerant to...
LA  - en
PB  - Springer
KW  - Fluoropyrimidine
KW  - Metastatic colorectal cancer
KW  - Spain
KW  - TAS-102
KW  - Tipiracil hydrochloride
KW  - Trifluridine
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antiviral Agents
KW  - Colorectal Neoplasms
KW  - Double-Blind Method
KW  - Drug Combinations
KW  - Drug Therapy, Combination
KW  - Female
KW  - Follow-Up Studies
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Neoplasm Staging
KW  - Palliative Care
KW  - Prognosis
KW  - Pyrrolidines
KW  - Spain
KW  - Survival Rate
KW  - Thymine
KW  - Trifluridine
KW  - Uracil
TI  - Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial.
TY  - research article
VL  - 19
ER  -